|
Jun 12
|
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
|
|
Jun 10
|
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
|
|
Mar 14
|
WEX, Lamb Weston, and More Stocks See Action From Activist Investors
|
|
Mar 12
|
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
|
|
Feb 28
|
Innoviva Full Year 2024 Earnings: EPS: US$0.37 (vs US$2.75 in FY 2023)
|
|
Feb 26
|
Innoviva: Q4 Earnings Snapshot
|
|
Feb 26
|
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
|
|
Feb 6
|
Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
|
|
Sep 30
|
Innoviva, Inc.'s (NASDAQ:INVA) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
|
|
Jun 18
|
Apple downgraded, Kroger upgraded: Wall Street's top analyst calls
|
|
Jun 6
|
Calculating The Fair Value Of Innoviva, Inc. (NASDAQ:INVA)
|
|
Jun 3
|
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
|
|
May 10
|
Innoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed Analysis
|
|
May 10
|
Innoviva First Quarter 2024 Earnings: EPS: US$0.58 (vs US$0.51 in 1Q 2023)
|
|
May 8
|
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
|
|
May 8
|
Innoviva to Participate in the BofA Securities Health Care Conference
|
|
Apr 24
|
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
|
|
Apr 22
|
Should Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
|
|
Mar 4
|
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
|
|
Jan 10
|
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
|